Oncolytics Biotech Inc.
4660 La Jolla Village Drive
499 articles with Oncolytics Biotech Inc.
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022.
Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference.
Oncolytics Biotech® Inc. announced recent operational highlights and financial results for the first quarter ended March 31, 2022.
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Oncolytics Biotech® Inc. and SOLTI-Innovative Cancer Research today announced new clinical biomarker data demonstrating pelareorep's immunotherapeutic effects, synergy with checkpoint inhibition, and potential to improve the outlook for patients with HR+/HER2- breast cancer.
Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting
Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Meeting.
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Thursday, May 5, 2022, at 5:00 p.m. ET to discuss a corporate update and financial results for the first quarter of 2022.
Oncolytics Biotech will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference, which is taking place May 2-3, 2022 at the Metro Toronto Convention.
Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine
Oncolytics Biotech® Inc. today announced the publication of preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with chimeric antigen receptor (CAR) T cell therapy in solid tumors.
Researchers are combining CAR-T cell therapy with cancer-killing viruses to create an even more potent treatment against solid cancer tumors.
Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Thomas Heineman, M.D., Ph.D., the Company's Chief Medical Officer, will be participating in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference.
Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting featuring new clinical biomarker data from a completed investigator-sponsored phase 1b trial of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients.
Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive long-term survival data from ReoGlio, an investigator-sponsored phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM).
Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders.
Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial
Oncolytics Biotech Inc.® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the third-line metastatic colorectal cancer (mCRC) cohort of the phase 1/2 GOBLET study, following an independent review by the study's Data Safety Monitoring Board (DSMB).
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort
[24-March-2022] First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep's development in large and rapidly growing pharmaceutical markets, including China , Hong Kong , Macau , Taiwan , Singapore , and South Korea Final cohort's
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology.
Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.
Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting
Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma.
Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced an upcoming poster presentation that will feature long-term follow-up results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep.